Physician profile
Katherine Combs
NPI 1013677699
$3,022.21
in general payments reported to CMS, 2019-2025
22 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $434 · 2023: $748 · 2024: $1,568 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.50 | 2023-2025 | |
| Pfizer INC. | $535.67 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $232.35 | 2022-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Biohaven Pharmaceutical Holding Company Ltd. | $180.07 | 2022 | |
| Sk Life Science, INC. | $160.87 | 2023-2024 | Xcopri |
| Sumitomo Pharma America, INC. | $115.41 | 2023-2024 | Aptiom |
| Genentech USA, INC. | $115.34 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $105.63 | 2022-2024 | Nayzilam, Briviact |
| Neurocrine Biosciences, INC. | $99.23 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $75.33 | 2022-2025 | Reyvow, Emgality, Kisunla |
| Sunovion Pharmaceuticals INC. | $56.25 | 2022 | |
| Neurelis, INC. | $41.96 | 2024 | Valtoco |
| Amgen INC. | $31.97 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $31.19 | 2024 | Relyvrio |
| Azurity Pharmaceuticals, INC. | $30.72 | 2024 | Horizant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.62 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $19.07 | 2024 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $16.57 | 2024 | Xeomin |
| Abbott Laboratories | $16.42 | 2024 | Infinity |
| Acadia Pharmaceuticals INC | $14.06 | 2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $12.98 | 2023 | Nuedexta |
| Acorda Therapeutics, INC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.